• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt1): powerful new tools to guide obstetric and medical care in pregnancy.

作者信息

Gladstone Rachel A, Snelgrove John W, McLaughlin Kelsey, Hobson Sebastian R, Windrim Rory C, Melamed Nir, Hladunewich Michelle, Drewlo Sascha, Kingdom John C

机构信息

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, Canada.

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology, Sunnybrook Health Sciences Centre, University of Toronto, Canada.

出版信息

Obstet Med. 2025 Apr 3:1753495X251327462. doi: 10.1177/1753495X251327462.

DOI:10.1177/1753495X251327462
PMID:40191640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11969481/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf4/11969481/8c03ef3d4ea8/10.1177_1753495X251327462-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf4/11969481/7440222b65b1/10.1177_1753495X251327462-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf4/11969481/8c03ef3d4ea8/10.1177_1753495X251327462-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf4/11969481/7440222b65b1/10.1177_1753495X251327462-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf4/11969481/8c03ef3d4ea8/10.1177_1753495X251327462-fig2.jpg

相似文献

1
Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt1): powerful new tools to guide obstetric and medical care in pregnancy.胎盘生长因子（PlGF）和可溶性fms样酪氨酸激酶-1（sFlt1）：指导孕期产科和医疗护理的强大新工具。
Obstet Med. 2025 Apr 3:1753495X251327462. doi: 10.1177/1753495X251327462.
2
Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction.胎盘 sFLT1（可溶性 fms 样酪氨酸激酶受体 1）增加导致子痫前期前母体血清的抗血管生成特征，但不导致胎儿生长受限。
Hypertension. 2023 Feb;80(2):325-334. doi: 10.1161/HYPERTENSIONAHA.122.19482. Epub 2022 Jul 22.
3
Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?双胎妊娠与子痫前期风险：胎盘更大还是相对缺血？
Am J Obstet Gynecol. 2008 Apr;198(4):428.e1-6. doi: 10.1016/j.ajog.2007.10.783. Epub 2008 Jan 14.
4
Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.可溶性 fms 样酪氨酸激酶-1 和可溶性内皮糖蛋白在 HIV 相关子痫前期中的作用。
Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):100-5. doi: 10.1016/j.ejogrb.2013.05.021. Epub 2013 Jun 24.
5
The ratio of soluble fms-like tyrosine kinase 1 to placental growth factor predicts time to delivery and mode of birth in patients with suspected preeclampsia: a secondary analysis of the INSPIRE trial.可溶性fms样酪氨酸激酶1与胎盘生长因子的比值可预测疑似子痫前期患者的分娩时间和分娩方式：INSPIRE试验的二次分析
Am J Obstet Gynecol. 2025 Mar;232(3):317.e1-317.e17. doi: 10.1016/j.ajog.2024.06.010. Epub 2024 Jun 17.
6
The clinical value of PlGF and the sFlt1/PlGF ratio in the management of hypertensive pregnancy disorders: A retrospective real-world study in China.胎盘生长因子和可溶性 fms 样酪氨酸激酶 1/胎盘生长因子比值在高血压妊娠疾病管理中的临床价值：中国的回顾性真实世界研究。
Clin Chim Acta. 2022 Mar 1;528:90-97. doi: 10.1016/j.cca.2022.01.021. Epub 2022 Jan 29.
7
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.过量的胎盘可溶性fms样酪氨酸激酶1（sFlt1）可能导致子痫前期的内皮功能障碍、高血压和蛋白尿。
J Clin Invest. 2003 Mar;111(5):649-58. doi: 10.1172/JCI17189.
8
Individual exposure to urban air pollution and its correlation with placental angiogenic markers in the first trimester of pregnancy, in São Paulo, Brazil.个体暴露于城市空气污染与巴西圣保罗妊娠早期胎盘血管生成标志物的相关性。
Environ Sci Pollut Res Int. 2021 Jun;28(22):28658-28665. doi: 10.1007/s11356-021-12353-7. Epub 2021 Feb 5.
9
Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform.在B·R·A·H·M·S KRYPTOR Compact Plus全自动免疫分析平台上对可溶性fms样酪氨酸激酶和胎盘生长因子检测进行分析验证。
Pregnancy Hypertens. 2018 Jan;11:66-70. doi: 10.1016/j.preghy.2017.12.009. Epub 2018 Jan 2.
10
Biomarker Immunoassays in the Diagnosis of Preeclampsia: Calculating the sFlt1/PlGF Ratio Using the Cobase 411 Analyser.生物标志物免疫测定法在子痫前期诊断中的应用：使用Cobase 411分析仪计算可溶性血管内皮生长因子受体1（sFlt1）/胎盘生长因子（PlGF）比值
Methods Mol Biol. 2018;1710:9-26. doi: 10.1007/978-1-4939-7498-6_2.

本文引用的文献

1
Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia.胎盘靶向血管内皮生长因子信使核糖核酸脂质纳米粒改善小鼠子痫前期。
Nature. 2025 Jan;637(8045):412-421. doi: 10.1038/s41586-024-08291-2. Epub 2024 Dec 11.
2
First-Trimester PlGF and PAPP-A and the Risk of Placenta-Mediated Complications: PREDICTION Prospective Study.孕早期胎盘生长因子和妊娠相关血浆蛋白A与胎盘介导并发症的风险：PREDICTION前瞻性研究
J Obstet Gynaecol Can. 2025 Feb;47(2):102732. doi: 10.1016/j.jogc.2024.102732. Epub 2024 Dec 2.
3
Midpregnancy Placental Growth Factor Screening and Early Preterm Birth.
中孕期胎盘生长因子筛查与早产。
JAMA Netw Open. 2024 Nov 4;7(11):e2444454. doi: 10.1001/jamanetworkopen.2024.44454.
4
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial.24-28 周胎盘生长因子用于有早产先兆子痫高危风险的孕妇停用阿司匹林：StopPRE 试验的事后分析。
Acta Obstet Gynecol Scand. 2024 Nov;103(11):2273-2280. doi: 10.1111/aogs.14955. Epub 2024 Aug 22.
5
Investigation and Care of a Small-for-Gestational-Age Fetus and a Growth Restricted Fetus (Green-top Guideline No. 31).小于胎龄儿和胎儿生长受限的调查与处理（绿皮书指南第31号）
BJOG. 2024 Aug;131(9):e31-e80. doi: 10.1111/1471-0528.17814. Epub 2024 May 13.
6
Phenotypes of maternal vascular malperfusion placental pathology and adverse pregnancy outcomes: A retrospective cohort study.母体血管功能不全性胎盘病理学表型与不良妊娠结局：一项回顾性队列研究。
BJOG. 2024 Oct;131(11):1515-1523. doi: 10.1111/1471-0528.17837. Epub 2024 May 9.
7
Angiogenic Biomarkers in Preeclampsia.子痫前期的血管生成生物标志物。
Obstet Gynecol. 2024 Apr 1;143(4):515-523. doi: 10.1097/AOG.0000000000005532. Epub 2024 Feb 13.
8
Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.在疑似早产子痫前期（PARROT-2）的女性中重复胎盘生长因子检测：一项多中心、平行组、优效性、随机对照试验。
Lancet. 2024 Feb 17;403(10427):619-631. doi: 10.1016/S0140-6736(23)02357-7. Epub 2024 Feb 8.
9
Calcium supplementation for the prevention of pre-eclampsia: Challenging the evidence from meta-analyses.补钙预防子痫前期：对荟萃分析证据的挑战。
BJOG. 2024 Oct;131(11):1524-1529. doi: 10.1111/1471-0528.17769. Epub 2024 Feb 1.
10
Placental growth factor testing at 19-23 weeks of gestation as a guide to subsequent care in pregnancy: A prospective observational study.妊娠 19-23 周时胎盘生长因子检测作为后续妊娠护理指导：一项前瞻性观察性研究。
BJOG. 2024 May;131(6):803-810. doi: 10.1111/1471-0528.17684. Epub 2023 Oct 24.